A Frier Levitt attorney published an article, “Regulatory Considerations Regarding the 503B to 503A Compounding Model For Community Pharmacies” in Pharmacy Times.
On June 27, 2023, the FDA issued draft guidance allowing 503A pharmacies to purchase compounded medications from 503B facilities for patient dispensing. The 503B to 503A model is relatively new, necessitating pharmacies to stay updated on any developments. The article provides a checklist for pharmacies to follow when purchasing from a 503B outsourcing facility.
Read the article here: https://www.pharmacytimes.com/view/regulatory-considerations-regarding-the-503b-to-503a-compounding-model-for-community-pharmacies
